Article Text

other Versions

PDF
Randomised controlled trial
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection
  1. Diego Ripamonti
  1. Infectious Diseases Unit, Azienda Ospedaliera Papa Giovanni XXIII, Piazza, Italy
  1. Correspondence to: Dr Diego Ripamonti, Infectious Diseases Unit, Azienda Ospedaliera Papa Giovanni XXIII, Piazza OMS 1, Bergamo 24127, Italy; diego.ripamonti{at}hotmail.com

Statistics from Altmetric.com

Commentary on: OpenUrl

Context

Over the last 20 years, little has changed in terms of HIV treatment paradigm, being a three-drug regimen the standard of care for initial therapy. However, for reasons of virological plausibility, toxicity and costs, clinical researchers have explored the alternatives of switching virologically controlled patients to less-drug regimens (ie, dual or monotherapy). Several randomised trials1 investigated the ritonavir-boosted protease inhibitor monotherapy (PI-mono), on the grounds of absence of resistance …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.